Overexpression of COX2 indicates poor survival in urothelial bladder cancer
| Autor: | Nayan K. Mohanty, Usha Agrawal, Sunita Saxena, Pawan Vasudeva, Nitu Kumari |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Pathology medicine.medical_specialty Stromal cell Kaplan-Meier Estimate macromolecular substances Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Downregulation and upregulation Gene expression Humans Medicine Urothelial carcinoma Inflammation chemistry.chemical_classification Bladder cancer business.industry Carcinoma food and beverages General Medicine Middle Aged Prognosis medicine.disease Immunohistochemistry Up-Regulation 030104 developmental biology Enzyme Urinary Bladder Neoplasms chemistry Cyclooxygenase 2 030220 oncology & carcinogenesis Disease Progression Normal bladder Female Neoplasm Recurrence Local business |
| Zdroj: | Annals of Diagnostic Pathology. 34:50-55 |
| ISSN: | 1092-9134 |
| DOI: | 10.1016/j.anndiagpath.2018.01.008 |
| Popis: | Background COX2 is a cyclo-oxygenase enzyme expressed in the tumor cells, inflammatory cells, stromal and non-epithelial cells. The study was conducted to evaluate the expression of COX2 in Urothelial carcinoma and find the association with progression and recurrence. Methods The expression of COX2 was evaluated by real-time PCR and immunohistochemistry. Results Gene expression of COX2 was found to be upregulated >28-fold in urothelial cancer compared to adjacent normal bladder mucosa. Inflammatory cell expression of COX2 was found in 92% cases whereas only 37% cases showed COX2 overexpression in tumor cells. Tumor cell COX2 overexpression was significantly associated with invasion and recurrence. Conclusion COX2 expression is a marker of invasion, recurrence and poor survival and may have a role in predicting the cases which will benefit from additional treatment with COX2 inhibitors in urothelial carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect